A sodium alginate-based hydrogel microscaffold composite system, its preparation method and application

By using a composite system of peptide-modified sodium alginate hydrogel and porous microscaffold, the shortcomings of Matrigel matrix gel are overcome, enabling rapid drug sensitivity testing of tumor organoids. This system provides stable support and efficient drug penetration, and is suitable for three-dimensional culture and drug sensitivity testing of various solid tumor organoids.

CN123107930APending Publication Date: 2026-11-17CHENGDU MINSHAN CHUANGXIN BIOCHIP TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202610576284.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Among existing three-dimensional culture technologies for tumor organoids, Matrigel has problems such as uncertain composition, large batch-to-batch variability, animal-derived biosafety risks, poor drug permeability, and long drug sensitivity testing cycle, making it difficult to achieve standardized application and clinical translation.

Method used

A composite system of peptide-modified sodium alginate hydrogel and sodium alginate-based porous microscaffold was used to prepare porous microspheres through spray crosslinking and freeze-drying. Combined with the synergistic effect of RGD, QK, VN and YGGFM peptides, a simulated in vivo tumor microenvironment was constructed to improve drug sensitivity response.

Benefits of technology

It significantly shortens the drug sensitivity testing cycle, improves drug penetration efficiency, provides stable physical support and enriched nutrient microenvironment, enables rapid drug sensitivity testing, and results are closer to the actual clinical drug use effect, avoiding the risks of animal-derived components.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107930A_ABST
    Figure CN123107930A_ABST
Patent Text Reader

Abstract

This invention discloses a sodium alginate-based hydrogel microscaffold composite system, its preparation method, and its applications, specifically relating to the field of medical materials technology. The hydrogel microscaffold composite system is composed of a peptide-modified sodium alginate hydrogel and a sodium alginate-based porous microscaffold. The peptide-modified sodium alginate hydrogel is prepared by mixing a sodium alginate solution grafted with cell adhesion and growth factor mimicry peptides, wherein the peptides include at least RGD, QK, VN, and YGGFM. The sodium alginate-based porous microscaffold is a porous microsphere prepared by spray crosslinking and freeze-drying using sodium alginate and carboxymethyl chitosan as substrates and sodium bicarbonate as a pore-forming agent. The hydrogel microscaffold composite system of this invention exhibits excellent drug permeability, with significant tumor organoid killing effects detectable within 24 hours after drug administration. The drug response speed is significantly faster than the traditional Matrigel system, greatly shortening the drug sensitivity testing cycle and meeting the urgent clinical need for rapid drug administration guidance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medical materials technology, specifically to a sodium alginate-based hydrogel microscaffold composite system, its preparation method, and its application. Background Technology

[0002] Tumor organoids, as patient-derived in vitro three-dimensional tumor models, can highly replicate the tissue morphology, gene expression characteristics, and drug response patterns of tumors in vivo, possessing irreplaceable value in tumor pathological mechanism research, new drug screening, and personalized precision treatment. In particular, patient-derived tumor organoids (PDOs) have been successfully constructed for various solid tumors such as colorectal cancer, lung cancer, gastric cancer, and breast cancer, becoming an important in vitro tool for clinical drug screening and efficacy prediction.

[0003] Currently, mouse-derived Matrigel is commonly used as a three-dimensional scaffold for in vitro culture of tumor organoids. Matrigel is an extract from mouse sarcoma, and although it can support organoid growth, it has drawbacks such as uncertain composition, large batch-to-batch variability, animal-derived biosafety risks, poor drug permeability, and long drug sensitivity testing cycles, which seriously restrict its standardized application and clinical translation.

[0004] To replace animal-derived matrices, natural polysaccharide-based hydrogels have become a research focus. Sodium alginate (SA) has good biocompatibility and convenient ionic cross-linking, making it an ideal scaffold substrate. Among existing technologies: CN115873266A discloses a peptide-grafted sodium alginate-chitosan antibacterial gel, mainly used for medical dressings, not related to organoid culture; CN118649128A discloses an injectable RGD-sodium alginate hydrogel, mainly used for endometrial repair, not for tumor organoid drug sensitivity testing; CN120714100A discloses a multi-component peptide-modified sodium alginate hydrogel, which can enhance cell adhesion, but the three-dimensional support and mass transfer efficiency of the single-phase gel are limited; CN121102575A discloses a sodium alginate-chitosan porous microscaffold, which can provide structural support, but its stability is insufficient when used alone.

[0005] CN121495859A further combines the aforementioned peptide-modified sodium alginate hydrogel with porous microscaffolds to construct a hydrogel-microscaffold composite system, achieving three-dimensional culture of various tumor organoids. However, this technology still has significant shortcomings: it only achieves basic organoid culture and has not established a standardized method for quantitative evaluation of drug sensitivity; the system is not optimized for rapid drug penetration, resulting in a long response time; it has not been compared head-to-head with Matrigel for drug sensitivity, and its reliability and clinical relevance lack validation; the microscaffold preparation process is crude, and particle size uniformity, swelling performance, and adsorption capacity need to be improved; the peptide combination is simple, limiting its ability to regulate the tumor microenvironment and making it difficult to meet the needs of rapid drug sensitivity detection.

[0006] Therefore, developing an optimized sodium alginate hydrogel microscaffold composite system that can significantly shorten the detection cycle, improve drug penetration efficiency, and accurately predict clinical efficacy has important clinical value. Summary of the Invention

[0007] Therefore, this invention provides a sodium alginate-based hydrogel microscaffold composite system, its preparation method, and its application to solve the problems in the prior art.

[0008] To achieve the above objectives, the present invention provides the following technical solution: According to a first aspect of the present invention, a sodium alginate-based hydrogel microscaffold composite system is composed of a polypeptide-modified sodium alginate hydrogel and a sodium alginate-based porous microscaffold. The polypeptide-modified sodium alginate hydrogel is prepared by mixing sodium alginate solution grafted with cell adhesion and growth factor mimicry polypeptides, wherein the polypeptides include at least RGD, QK, VN and YGGFM. The sodium alginate-based porous microscaffold is a microsphere with a porous structure prepared by spray crosslinking and freeze-drying using sodium alginate and carboxymethyl chitosan as substrates and sodium bicarbonate as a pore-forming agent.

[0009] Furthermore, in the polypeptide-modified sodium alginate hydrogel, the volume ratio of the sodium alginate solution grafted with RGD, QK, VN, and YGGFM polypeptides is (5-15):(5-15):(40-60):(20-40), preferably 10:10:50:30; the molar ratio of the polypeptide to sodium alginate is 1:10-1:30, preferably 1:15-1:20.

[0010] The sodium alginate hydrogel grafted with the four polypeptides (RGD, QK, VN, and YGGFM) described in this invention enhances the drug sensitivity detection of tumor organoids not through a simple additive effect of the individual polypeptides, but through synergistic interactions between them. The introduction of YGGFM (growth factor mimic peptide) is particularly crucial; it, along with RGD (cell adhesion peptide), QK (angiogenesis mimic peptide), and VN (extracellular matrix adhesion peptide), constructs a bioactive interface that mimics the in vivo tumor microenvironment, thereby significantly improving the drug sensitivity response of tumor organoids.

[0011] Furthermore, in the sodium alginate-based porous microscaffold, the concentration of sodium alginate solution is 1.5%-4% (preferably 2%-3%), the concentration of carboxymethyl chitosan solution is 1%-5% (preferably 3%), and the volume ratio of the two is 1:0.5-1:2 (preferably 1:1).

[0012] Furthermore, the crosslinking agent of the microscaffold is a 30%-70% ethanol solution containing 4%-8% anhydrous calcium chloride (preferably a 50% ethanol solution containing 6% anhydrous calcium chloride); the particle size of the microscaffold after swelling is 100-500μm (preferably 200-300μm), and the swelling rate is ≥150% (preferably ≥170%).

[0013] The composite system of the present invention is a three-dimensional culture medium with no animal origin and clearly defined components, which is suitable for the culture, amplification and antitumor drug sensitivity detection of tumor organoids.

[0014] According to a second aspect of the present invention, a method for preparing a sodium alginate-based hydrogel microscaffold composite system as described above is characterized by comprising the following steps: (1) RGD-sodium alginate, QK-sodium alginate, VN-sodium alginate and YGGFM-sodium alginate solutions were prepared by EDC / NHS activation method and mixed in proportion to obtain peptide-modified sodium alginate hydrogel precursor. (2) The above-mentioned polypeptide-modified sodium alginate hydrogel precursor solution was mixed with carboxymethyl chitosan solution, and pore-forming agent NaHCO3 was added. Calcium chloride ethanol solution was used as the crosslinking liquid. The mixture was spray-granulated, cured, washed, and freeze-dried to obtain sodium alginate-based porous microscaffold. (3) The polypeptide-modified sodium alginate hydrogel precursor and sodium alginate-based microscaffold are mixed in a certain proportion to prepare the composite system.

[0015] Furthermore, the activation and grafting conditions in step (1) are as follows: the crosslinking agent of the microscaffold is a 30%-70% ethanol solution containing 4%-8% anhydrous calcium chloride; the particle size of the microscaffold after swelling is 100-500μm, and the swelling rate is ≥150%.

[0016] Specifically, the activation and grafting conditions are as follows: activation is performed using 0.5X-2X EDC / NHS activation solution (preferably 1X) for 0.5-3h (preferably 1h), followed by standing for 1-5h (preferably 3h), and the grafting reaction is carried out at 0-10℃ (preferably 4℃) for 12-48h (preferably 20h); the mixing conditions are 15-37℃ (preferably 25℃) and stirring at 100-500rpm (preferably 250rpm) for 2-8h (preferably 4h).

[0017] Furthermore, the spraying process parameters in step (2) are as follows: nozzle distance from the crosslinking agent liquid surface is 8-20cm (preferably 12cm), pressure is 0.01-0.1Pa (preferably 0.02Pa), feed rate is 5-30rpm / min (preferably 15rpm / min); crosslinking curing time is 0.5-3h (preferably 1h); freeze drying time is 2-5 days (preferably 3 days).

[0018] This invention also provides a method for three-dimensional culture of tumor organoids using the above-mentioned composite system, comprising the following steps: (1) Mix the hydrogel with the tumor organoid basal culture medium at a volume ratio of 1:0.5-1:2 (preferably 1:1), and use a double syringe to push back and forth 10-30 times (preferably 15-20 times) to mix evenly; (2) Mix the tumor organoid cell suspension with the microscaffold, centrifuge at 1000-2000 rpm (preferably 1500 rpm) for 1-5 min (preferably 3 min), and retain 50-200 μL (preferably 100 μL) of supernatant; (3) Mix the mixture obtained in step (1) with the cell-microscaffold precipitate obtained in step (2) and press it back and forth 10-30 times (preferably 15-20 times) with a dual syringe. (4) Take 30-100 μL (preferably 50 μL) and inoculate it into a culture plate (preferably a 96-well low-adsorption plate), let it stand at 0-10℃ (preferably 2-8℃) for 10-60 min (preferably 30 min) to form a soft gel, and cover it with 50-200 μL (preferably 100 μL) of culture medium for culture.

[0019] According to a third aspect of the present invention, an application of the sodium alginate-based hydrogel microscaffold composite system as described above in the preparation of three-dimensional culture products of tumor organoids or antitumor drug sensitivity detection products is provided.

[0020] The tumor organoids include, but are not limited to, one or more of the following: gastric cancer organoids, lung adenocarcinoma organoids, colorectal cancer organoids, or breast cancer organoids.

[0021] The antitumor drugs include, but are not limited to, cisplatin and / or oxaliplatin.

[0022] The drug sensitivity test measures the killing effect of the drug on tumor organoids within 24-72 hours after drug administration. Preferably, the ATP chemiluminescence method is used to quantitatively reflect the number of viable cells by measuring intracellular ATP content and calculating the IC50. 50 value.

[0023] The present invention has the following advantages: The hydrogel microscaffold composite system provided by this invention has excellent drug permeability. Significant tumor organoid killing effect can be detected within 24 hours after drug administration. The drug response speed is significantly faster than that of the traditional Matrigel system, which can greatly shorten the drug sensitivity detection cycle and meet the urgent clinical need for rapid drug administration guidance.

[0024] Taking cisplatin, a commonly used chemotherapy drug in clinical practice, as an example, lung adenocarcinoma organoids were cultured using the composite system of this invention, and the IC50 was measured 24 hours after drug administration. 50The concentration was 63.97 μM, while the IC50 of the traditional Matrigel system under the same conditions was much higher. 50 The concentration reached as high as 844.4 μM. The detection results of this invention are closer to the actual clinical drug concentration, and can more realistically and accurately reflect the drug sensitivity of the patient's tumor, providing a reliable basis for individualized clinical medication.

[0025] This invention uses plant-based sodium alginate and synthetic peptides as the main raw materials, containing no animal-derived components, thus fundamentally avoiding the immunogenicity risks and foreign protein contamination associated with traditional matrix gels. The system has clearly defined components and a fixed formulation, ensuring high batch-to-batch consistency, enabling standardized, large-scale production and clinical translation applications.

[0026] This invention simultaneously grafts four functional peptides: RGD cell adhesion peptide, QK angiogenesis mimic peptide, VN extracellular matrix adhesion peptide, and YGGFM growth factor mimic peptide. By employing an optimized ratio of these peptides, they synergistically provide cell adhesion, proliferation, migration, and signal regulation, significantly enhancing organoid growth activity and structural stability, and more closely mimicking the physiological microenvironment of tumors in vivo.

[0027] This invention utilizes sodium alginate and carboxymethyl chitosan as substrates and NaHCO3 as a pore-forming agent to prepare a microscaffold through an optimized spray freeze-drying process. This microscaffold has a porous structure, a particle size of 200-300 μm after swelling, and a swelling rate of ≥170%. It can efficiently adsorb small molecule drugs and large molecule proteins, providing stable physical support and enriched nutrient microenvironment for organoids, and significantly improving the uniformity of organoid growth.

[0028] This invention employs a dual-syringe mixing process and low-temperature rapid gel formation, making it simple to operate and requiring no special equipment. The gel formation conditions are mild, and the inoculation volume is small, enabling high-throughput culture and drug sensitivity testing directly in 96-well plates. It is easily automated and suitable for large-scale clinical screening. This invention has been successfully used for three-dimensional culture and drug sensitivity testing of various solid tumor organoids, including human gastric cancer, lung adenocarcinoma, colorectal cancer, and breast cancer. The models are stable, reproducible, and have broad clinical applicability and promotional value. Attached Figure Description

[0029] To more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings in the following description are merely exemplary, and those skilled in the art can derive other embodiments based on the provided drawings without creative effort.

[0030] The structures, proportions, sizes, etc. illustrated in this specification are only for the purpose of assisting those skilled in the art in understanding and reading the content disclosed herein, and are not intended to limit the conditions under which the present invention can be implemented. Therefore, they have no substantial technical significance. Any modifications to the structure, changes in the proportions, or adjustments to the size, without affecting the effects and objectives that the present invention can produce, should still fall within the scope of the technical content disclosed in the present invention.

[0031] Figure 1 This is a SEM image of the surface microstructure of a sodium alginate-based microscaffold provided in Embodiment 1 of the present invention. Figure 1 Image A is a 200x magnified image of the microscaffold under a scanning electron microscope. Figure 1 B is Figure 1 A photograph magnified 40,000 times in a specific area; Figure 2 The graph shows the BET adsorption performance of the sodium alginate-based microscaffold provided in Embodiment 1 of the present invention. Figure 3 The adsorption curve of small molecule subunit blue on the sodium alginate-based microscaffold provided in Example 1 of the present invention is shown. Figure 4 The images are taken using a fluorescence microscope to show the adsorption of macromolecule FITC-bovine serum albumin by the sodium alginate-based microscaffold provided in Example 1 of this invention. In the images, a is the observation under a fluorescence field, b is the observation under a bright field, and c is the superposition of a and b. Figure 5 The effects of different concentrations of cisplatin on gastric cancer organoids in a hydrogel microscaffold matrix composite system 24 hours after drug administration, as provided in Example 2 of this invention, are as follows: A - negative control group; B - 3.125 μM; C - 6.25 μM; D - 12.5 μM; E - 25 μM; F - 50 μM; G - 100 μM. Figure 6 The changes in ATP content in gastric cancer organoids treated with different concentrations of cisplatin 24 hours after drug administration, as provided in Example 2 of this invention; Figure 7 Cisplatin provided in Embodiment 2 of the present invention is effective for gastric cancer organoid ICs in a hydrogel microscaffold matrix composite system. 50 value; Figure 8 The effects of different concentrations of cisplatin on lung adenocarcinoma organoids in a hydrogel microscaffold matrix composite system were observed 24 hours after drug administration, as provided in Example 3 of this invention. A - negative control group; B - 3.125 μM; C - 6.25 μM; D - 12.5 μM; E - 25 μM; F - 50 μM; G - 100 μM. Figure 9Following cisplatin administration 24 hours after the application of cisplatin provided in Example 3 of this invention, the effect on the intracellular matrix (ICV) of lung adenocarcinoma organoids in the hydrogel microscaffold matrix composite system was observed. 50 value; Figure 10 24 hours after cisplatin administration as provided in Example 3 of this invention, the IC50 of lung adenocarcinoma organoids in the Matrigel system (Matrigel control group) was [affected / ...]. 50 value; Figure 11 The effect of oxaliplatin dosing 24 hours after administration on the viability of colorectal cancer organoid cells in the hydrogel microscaffold matrix composite system provided in Example 4 of the present invention; Figure 12 This is a SEM image of the microscaffold provided in Comparative Example 3 of the present invention. Detailed Implementation

[0032] The following specific embodiments illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Obviously, the described embodiments are only some, not all, of the embodiments of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0033] Unless otherwise specified in the embodiments of this invention, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available products; different manufacturers and models of raw materials do not affect the implementation of the technical solution or the achievement of the technical effect of this invention.

[0034] The reagents and instruments used in the following examples are as follows: Sodium alginate (SA, viscosity 86 mPa·S): Qingdao Mingyue Company; RGD peptide (sequence: GGGGRGDASSP-NH2), QK peptide (sequence: KLTWQELYQLKYKGI), VN peptide (sequence: KGGPQVTRGDVFTMP), YGGFM peptide (sequence: YGGFM-NH2): Qiangyao Biotechnology, purity ≥97%; EDC, NHS, MES: Aladdin, molecular biological grade; Anhydrous calcium chloride: Aladdin; Carboxymethyl chitosan (200-400 mPS, degree of deacetylation ≥95%): Aladdin; Tumor organoid basal culture medium: self-made (formula below) Human gastric cancer tissue, lung adenocarcinoma tissue, and colorectal cancer tissue: derived from surgical specimens removed in hospitals, with informed consent from patients; 96-well low-adsorption culture plate: Corning; Spray freeze-drying granulation equipment: Tokyo Rika SFD-1000; Refrigerated Dryer: LGJ-12D departs from Beijing's Fourth Ring Road; ATP assay kit: Promega CellTiter-Glo® 3D; Tumor organoid basal culture medium formulation: The basal medium, Advanced DMEM / F12, was supplemented with: 1×B27, 2mM GlutaMAX, 10mM HEPES, 10mM Nicotinamide, 1.5mM N-acetyl-L-cysteine, 1% Penicillin-Streptomycin, 1×N21-MAX Supplement, 100ng / mL Noggin, 500ng / mL R-Spondin 1, 50ng / mL EGF, and 10μM Y-27632.

[0035] Specific operational procedures for antitumor drug sensitivity testing: 1. Remove the hydrogel, which has been pre-allocated to EP tubes, from the 4°C freezer and incubate at 37°C with 5% CO2 for 30 min. Place the DMEM / F12, culture medium, 0.25% trypsin, and DPBS in a biosafety cabinet for natural incubation.

[0036] 2. Cell preparation: Digest cells with digestion solution. After digestion is stopped, transfer the cells to centrifuge tubes and centrifuge at 1500 rpm for 3 min. Discard all supernatant and resuspend the pellet in DMEM / F12 medium.

[0037] 3. Take 1 mL of cell suspension containing 60*2500=150,000 cells and transfer it to an EP tube. Add 10 μL of microscaffold powder to the tube using a pipette, mix by pipetting 10 times, and centrifuge at 1500 rpm for 3 min.

[0038] 4. Remove most of the supernatant, leaving 100 μL of supernatant (use a 1 mL pipette to directly remove 900 μL of supernatant), and resuspend the cell pellet for later use.

[0039] 5. The hydrogel microscaffold matrix composite system was mixed with cells using the injection mixing method: The volume of the supply and demand hydrogel microscaffold mixing system was 60*20ul=1.2mL. Two sterile syringes were used. One syringe was used to directly draw 600μL of hydrogel according to the syringe mark, and the other syringe was used to transfer 600μL of proliferation culture medium (from the syringe needle tip) to the syringe. After the air was expelled from the two syringes, they were connected with Luer tube connectors (mother-mother). After slowly pushing and pulling back and forth 20 times, the two syringes were separated and ready for use.

[0040] 6. Transfer all the cell / microscaffold precipitate from step 4 (from the syringe needle tip) to any of the syringes from step 5. Reconnect the two syringes and slowly push and pull back and forth 20 times to transfer all the precipitate into the EP tube.

[0041] 7. Use a pipette to take 50 μL of the mixed cell-hydrogel-microscaffold complex per well and plate it into a low-adsorption 96-well plate.

[0042] 8. After sealing the 96-well plate with sealing film, place it in a 4°C refrigerator for 10 minutes to stabilize the hydrogel microscaffold system. Remove the 96-well plate, add 100 μL of tumor organoid proliferation culture medium to each well using a pipette, and incubate the tumor organoids in a 37°C 5% CO2 incubator.

[0043] 9. Drug Addition: After culturing tumor organoids for 4 days, carefully add 150 μL of 2× drug working solution to each well, reaching the preset 1× final concentration. Gently shake the plate to mix, avoiding blowing away the organoids.

[0044] 10. Quantitative detection of intracellular ATP content: At 24h, 48h, and 72h after drug administration (3 time points; for the Matrigel group, testing is generally performed at 72h), the intracellular ATP content was measured by chemiluminescence to quantitatively detect the condition of living cells, determine the killing effect of the drug on cells in tumor organoids, and thus determine the drug sensitivity of antitumor drugs.

[0045] Example 1 (I) Preparation of polypeptide-modified sodium alginate hydrogel: 1.1 Solution Preparation (1) 0.1 mol / L MES buffer: Weigh 4.88 g MES and dissolve it in 225 mL of deionized water. Adjust the pH to 6.8 with 1 N NaOH and bring the volume to 250 mL. Filter the solution through a 0.22 μm filter membrane for sterilization.

[0046] (2) 100X EDC / NHS working solution: Weigh 0.06g NHS and 0.2g EDC and dissolve them in 20mL MES buffer, then filter through a 0.22μm filter membrane for sterilization.

[0047] (3) 1X EDC / NHS activation solution: Mix 1 mL of 100X working solution with 99 mL of sterile MES buffer.

[0048] (4) Working solution of peptides: RGD peptide (sequence: GGGRGDASSP-NH2), QK peptide (sequence: KLTWQELYQLYKYGI), VN peptide (sequence: KGGPQVTRGDVFTMP), and FYGGM peptide (sequence: FYGGM-NH2) were dissolved in DPBS to prepare a 20 mmol / L solution, and filtered through a 0.22 μm filter membrane for later use.

[0049] 1.2 Preparation of sodium alginate solution In a biosafety cabinet, add 30g of ultrapure sodium alginate to the bottom of the reaction flask, slowly add 300mL of tumor organoid basal culture medium along the flask wall, and incubate for 10min; stir at 50rpm for 30min; then add the remaining 700mL of culture medium and stir at 250rpm for 6h until completely dissolved.

[0050] 1.3 Sodium alginate activation and peptide grafting Add 3500 μL of 1X EDC / NHS activation solution to 1000 mL of sodium alginate solution, stir at 250 rpm for 1 h, and let stand at room temperature for 3 h to activate.

[0051] Take the activated sodium alginate solution and add it to the working solution of each peptide at a peptide:SA molar ratio of 1:15. Stir at 1000 rpm for 1 h and let stand at 4℃ for 20 h to obtain AR (RGD-SA), AQ (QK-SA), AV (VN-SA), and AY (YGGFM-SA) solutions respectively.

[0052] 1.4 Preparation of hydrogels The AR, AQ, AV, and AY solutions were transferred to a sterile reaction flask at a volume ratio of 10:10:50:30 and stirred at 250 rpm for 4 h to obtain a peptide-modified sodium alginate hydrogel, which was then stored at 4 °C for later use.

[0053] (II) Preparation of sodium alginate-based microscaffolds: 2.1 Preparation of Microscaffold Preparation Solution (1) Prepare 2% sodium alginate solution: Dissolve 2g SA in 100mL of tumor organoid basal culture medium and stir at 1000rpm for 4h at room temperature.

[0054] (2) Preparation of 2% AR, AQ, AV and AY solutions: Refer to the method in Example 1, but use 2% SA solution as raw material, and graft at the ratio of polypeptide:SA=1:15 to obtain 2% AR, 2% AQ, 2% AV and 2% AY solutions respectively.

[0055] (3) Mix 2% AR, 2% AQ, 2% AV and 2% AY in a volume ratio of 10:10:50:30 and stir at 600 rpm to obtain a polypeptide-modified sodium alginate hydrogel precursor solution.

[0056] (4) Mix the polypeptide-modified sodium alginate hydrogel precursor solution with 3% carboxymethyl chitosan solution at a volume ratio of 1:1, add pore-forming agent NaHCO3, stir evenly, and obtain microscaffold preparation solution.

[0057] 2.2 Preparation of crosslinking solution Add 60g of anhydrous calcium chloride to 1000mL of 50% ethanol solution at room temperature, stir to dissolve, and filter through a 0.22μm filter membrane.

[0058] 2.3 Spray granulation and cross-linking curing Add the crosslinking solution to a glass dish (23cm × 10cm) and place it directly below the nozzle of the spray freeze-drying granulation device, with the nozzle 12cm away from the liquid surface. Start the peristaltic pump at a pressure of 0.02Pa and pump the microscaffold preparation solution at a rate of 15rpm / min. The atomized liquid drips into the crosslinking solution to form microspheres, which are then cured for 1 hour.

[0059] 2.4 Washing and freeze-drying After cross-linking, the sample was filtered through a filter screen and rinsed three times with deionized water. After being rapidly frozen in liquid nitrogen, it was freeze-dried for 3 days to obtain a sodium alginate-based microscaffold (hereinafter referred to as "the microscaffold of this invention").

[0060] 2.5 Performance Characterization of Microscaffolds The morphology of the microscaffolds was observed using scanning electron microscopy (SEM), such as... Figure 1 A and Figure 1 As shown in Figure B, the results indicate that the microscaffolds have a porous structure, with a particle size of approximately 100-200 μm after lyophilization. When the microscaffolds are placed in tumor organoid basal culture medium, they rapidly swell within 30 minutes, with a particle size of 200-300 μm after swelling.

[0061] Table 1. BET data for micro-stents BET testing was used to obtain data related to the pore structure, such as... Figure 2 As shown; will Figure 2 The information regarding the mass, density, pore volume, and pore size of microscaffolds is compiled in Table 1. The porosity can be calculated using the following formula: Porosity = Pore volume / Sample volume = Pore volume / (mass / density) * 100% -----------------①; Figure 2As shown, the microscaffold adsorption isotherm lacks a distinct saturation adsorption plateau, exhibiting a composite hysteresis loop of types H1 and H3, indicating a non-uniform pore size distribution. The porosity of the microscaffold was calculated to be 17.5% using BET data (Table 1) and formula ①. In summary, the BET test results show that the microscaffold possesses a mesoporous structure with an average pore size of approximately 13.7 nm and a porosity of approximately 17.5%.

[0062] like Figure 3 and Figure 4 The adsorption experiments shown indicate that the microscaffold can effectively adsorb small molecule methylene blue (adsorption capacity reaches 0.540 g / g in 3 hours) and large molecule bovine serum albumin-FITC.

[0063] Example 2 Human gastric cancer organoids were cultured using a composite system, and cisplatin susceptibility testing was performed. 1. Obtaining human gastric cancer organoids Gastric cancer tissue removed during hospital surgery was minced and digested with 0.25% trypsin-EDTA for 30 min. After digestion was terminated, the tissue was centrifuged (1500 rpm, 3 min), the supernatant was discarded, and the tissue was resuspended in tumor organoid basal culture medium. Cells were counted and the cell density was adjusted to 2.5 × 10⁻⁶ cells / mL. 5 per mL.

[0064] 2. Composite system panel (1) Mixing hydrogel with culture medium: Take 1 mL of hydrogel from Example 1 and rewarm at 37℃ for 30 min. Take two sterile syringes, one to draw 500 μL of hydrogel and the other to draw 500 μL of tumor organoid basal culture medium. After removing the air, connect them with Luer connectors and push back and forth 15-20 times to mix.

[0065] (2) Mixing cells with microscaffolds: Take 1 mL of cell suspension containing 150,000 cells, add 10 μL of microscaffolds from Example 1, pipette and blow 10 times, centrifuge at 1500 rpm for 3 min, discard the supernatant, keep about 100 μL of supernatant, and resuspend the precipitate.

[0066] (3) Transfer the cell-microscaffold precipitate to the syringe of step (1) and mix by pushing back and forth 15-20 times to obtain a hydrogel-microscaffold-cell mixture.

[0067] (4) Using a 200μL wide-bore pipette tip, take 50μL of the mixture and add it to a 96-well low-adsorption plate. Gently tilt the plate to ensure even coverage. Seal the plate with a sealing film and let it stand at 4°C for 30 minutes to form a soft gel.

[0068] (5) Carefully add 100 μL of tumor organoid basal culture medium to each well and incubate at 37°C in a 5% CO2 incubator.

[0069] 3. Cisplatin susceptibility testing After 4 days of culture, the supernatant was aspirated, and 150 μL of fresh medium containing cisplatin was added to each well to achieve final cisplatin concentrations of 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM. An equal volume of DMSO was added to the negative control group. Each group had three replicates. Cell viability was assessed 24 hours after drug addition using the ATP chemiluminescence assay.

[0070] 4. Results Bright-field observation with an inverted microscope ( Figure 5 The results showed that as cisplatin concentration increased, the morphology of gastric cancer organoids gradually disintegrated, their number decreased, exhibiting a clear concentration-dependent killing effect. ATP detection results ( Figure 6 The results showed that after 24 hours of cisplatin treatment, intracellular ATP levels decreased with increasing drug concentration. (For example...) Figure 7 As shown, IC is calculated using GraphPad Prism 9. 50 The value was 39.81 μM. This indicates that cisplatin has a significant killing effect on gastric cancer organoids, significantly inhibits cell viability, and exhibits concentration-dependent inhibition.

[0071] Gastric cancer organoids cultured in a hydrogel microscaffold composite system can effectively detect and evaluate the cytotoxic effect of cisplatin, a first-line basic chemotherapy drug. In conclusion, human gastric cancer organoids cultured in this hydrogel microscaffold composite system can effectively detect the sensitivity of gastric cancer patients to cisplatin, a first-line basic chemotherapy drug.

[0072] Example 3 Human lung adenocarcinoma organoids were cultured using a composite system, and cisplatin susceptibility testing was performed. 1. Composite system group Human lung adenocarcinoma organoids were cultured according to the method in Example 2 (cell source: lung adenocarcinoma tissue surgically removed in a hospital), with the same cisplatin concentration gradient as above, and ATP was measured 24 hours after drug administration. Results ( Figure 8 , 9 Display IC 50 The value was 63.97 μM, indicating that the drug cisplatin has a significant killing effect on lung cancer organoids, significantly inhibits cell viability, and exhibits drug concentration gradient-dependent inhibition.

[0073] 2. Matrigel control group Lung adenocarcinoma cells from the same source were mixed with Matrigel (Corning, 356231) at a volume ratio of 1:1, and 10 μL was seeded into each well of a 96-well plate. After gelation at 37°C, culture medium was added. After 4 days of culture, the cells were treated with the same concentration of cisplatin for 24 h, and the results were detected by the ATP method. Figure 10 Display Matrigel group IC 50The value was 844.4 μM, which is much higher than that of the composite system group.

[0074] 3. Results Analysis Cisplatin IC measured by the microscaffold composite system of the present invention 50 The value (63.97 μM) is closer to the clinical drug concentration (the peak plasma concentration of cisplatin in lung cancer patients is approximately 5-20 μM; considering factors such as tissue binding, the in vitro sensitive concentration is usually in the range of 10-100 μM), while the IC50 value in the Matrigel group is much lower. 50 The value (844.4 μM) was significantly high, indicating that drug penetration in Matrigel was hindered, leading to distorted drug sensitivity test results. The composite system of this invention, due to the porous structure of the microscaffold and the good permeability of the hydrogel, allows drug molecules to rapidly diffuse into tumor organoids, achieving more accurate drug sensitivity assessment.

[0075] 24 hours after cisplatin administration, the IC50 of lung adenocarcinoma organoids in the hydrogel microscaffold matrix composite system was... 50 The value is much smaller than the IC50 value of lung adenocarcinoma organoids in the matrix gel system. 50 The value, and the IC50 of lung adenocarcinoma organoids in the hydrogel microscaffold matrix composite system. 50 The values ​​are closer to the clinically used concentration of cisplatin, a first-line basic chemotherapy drug. After 24 hours of drug treatment, the hydrogel group showed better drug sensitivity and responsiveness than the matrix gel group. The unusually large values ​​in the matrix gel group may be due to slower drug penetration and insufficient action time, leading to inadequate drug killing.

[0076] Example 4 Human colorectal cancer organoids cultured using a composite system and oxaliplatin susceptibility testing: Human colorectal cancer organoids (cell source: surgically removed colorectal cancer tissue from a hospital) were cultured according to the method in Example 2. After 4 days of culture, oxaliplatin was added at concentration gradients of 3.125-100 μM. Cell viability was measured by CCK8 assay after 24 hours. The results were as follows: Figure 11 The results showed that oxaliplatin has a significant concentration-dependent killing effect on colorectal cancer organoids. The drug oxaliplatin exhibits a significant killing effect on colorectal cancer organoids, significantly inhibits cell viability, and displays concentration-dependent inhibition, demonstrating that the microscaffold composite system of this invention is suitable for rapid drug sensitivity testing of various antitumor drugs.

[0077] Lung cancer organoids cultured in a hydrogel microscaffold composite system can effectively detect and evaluate the killing effects of various common antitumor drugs in clinical practice, providing a reference for clinical drug use. Furthermore, lung cancer organoids cultured in the hydrogel microscaffold composite system are superior to the mouse-derived Matrigel system commonly used in tumor organoid culture for drug sensitivity screening in clinical patients. This significantly shortens the drug sensitivity testing time and can quickly provide drug sensitivity results, offering an efficient, low-cost, and easily automated solution for assessing the effectiveness of clinical drug use.

[0078] Example 5 Peptide volume ratio optimization experiment To determine the optimal volume ratio of the peptide-modified sodium alginate solution, this example, based on Example 1, kept other conditions constant while adjusting the volume ratios of AR, AQ, AV, and AY to prepare hydrogels with different ratios. Gastric cancer organoids were cultured according to the method in Example 2, treated with 50 μM cisplatin for 24 h, and cell viability was assessed.

[0079] The results are shown in Table 2.

[0080] Table 2. Effect of different peptide volume ratios on cisplatin susceptibility. The results showed that cisplatin exhibited the best killing effect (lowest cell viability) at a volume ratio of 10:10:50:30, and the drug sensitivity decreased when deviating from this ratio. This indicates that the synergistic effect of the four peptides depends on a specific ratio range, with the preferred range being AR 5-15%, AQ 5-15%, AV 40-60%, and AY 20-40%, and the optimal ratio being 10:10:50:30.

[0081] Example 6 With other conditions fixed, AR solutions were prepared at peptide:SA molar ratios of 1:10, 1:15, 1:20, 1:25, and 1:30 (other peptides were kept at 1:15). After mixing into a hydrogel, the response of gastric cancer organoids to 50 μM cisplatin was tested according to the method in Example 2.

[0082] Results: Cell viability was 31.5% and 33.8% in the 1:15 and 1:20 groups, respectively; 39.2% in the 1:10 group; 37.5% in the 1:25 group; and 41.0% in the 1:30 group. This indicates that a good drug sensitivity effect can be achieved in the range of 1:10-1:30 for peptide grafting molar ratio, with 1:15-1:20 being the preferred ratio.

[0083] Example 7 The sodium alginate hydrogel grafted with the four polypeptides (RGD, QK, VN, YGGFM) described in this invention has a synergistic effect in the drug sensitivity detection of tumor organoids, rather than a simple superposition of the functions of each polypeptide. This comparative experiment was designed.

[0084] 1. Preparation of hydrogels with different peptide combinations: Referring to the preparation method of Example 1, the total concentration of hydrogel and the total molar ratio of grafted peptides were kept constant (the molar ratio of total peptides to sodium alginate was kept at 1:15), but the types and combinations of peptides were changed to prepare the following seven types of hydrogels: ① No peptides: pure sodium alginate hydrogel (no peptides grafted); ② RGD only, grafted only with RGD peptides; ③ QK only, grafted only with QK peptides; ④ VN only, grafted only with VN peptides; ⑤ YGGFM only, grafted only with YGGFM peptides; ⑥ RGD+QK+VN, grafted with RGD, QK, and VN peptides, but not with YGGFM; ⑦ A complete combination of RGD+QK+VN+YGGFM peptides (Example 1 of this invention).

[0085] In each group of hydrogels, the total molar grafting amount of peptides was kept consistent (all were 1:15 molar ratio). The single peptide group was grafted with only one peptide. The three peptide groups were mixed at a volume ratio of RGD:QK:VN=10:10:80 (to maintain the same relative ratio of RGD, QK, and VN as in the tetrapeptide group). The tetrapeptide group was mixed at a volume ratio of AR:AQ:AV:AY=10:10:50:30 as in Example 1.

[0086] 2. Tumor organoid culture and drug sensitivity testing Using the method described in Example 1, the above seven hydrogels were respectively combined with the microscaffolds of Example 1 to culture human gastric cancer organoids of the same origin. After 4 days of culture, 50 μM cisplatin was added for 24 h, and cell viability was detected by the ATP method (with the negative control without the drug as 100%). Each group was set with 3 replicates, and the experiment was repeated 3 times.

[0087] 3. Experimental Results The effects of different peptide combinations on the cisplatin sensitivity of hydrogels are shown in Table 3.

[0088] Table 3 Effects of different peptide combinations on cisplatin susceptibility in gastric cancer organoids (50 μM cisplatin, 24 h) As shown in Table 3: (1) Pure sodium alginate hydrogel without peptide grafting (group ①) showed the worst sensitivity to cisplatin, with cell viability as high as 71.3%, indicating that unmodified sodium alginate lacks cell adhesion sites, which is not conducive to organoid growth and drug response.

[0089] (2) Hydrogels grafted with single peptides (groups ②-⑤) can all improve the sensitivity of cells to cisplatin to varying degrees, and cell viability is reduced to between 54.8% and 61.5%. Among them, RGD peptide has the best effect (54.8%), but the improvement effect of single peptides is limited.

[0090] (3) The cell viability of the three polypeptide combinations (RGD+QK+VN, group ⑥) further decreased to 44.6%, which was significantly better than any single polypeptide group (p<0.01), indicating that there was a synergistic effect among the three polypeptides.

[0091] (4) The cell viability of the four polypeptide groups (group ⑦, i.e. Example 1 of the present invention) was the lowest, at only 31.5%, which was significantly different from the tripeptide group (44.6%) (p<0.01), and much lower than the arithmetic sum of the effects of each single peptide group (the average of the single peptide group was about 58%, and the expected value after the sum was much higher than 31.5%). This indicates that the addition of YGGFM polypeptide is not a simple sum of effects, but rather produces a significant synergistic effect with RGD, QK and VN polypeptides.

[0092] Example 8 The rapid response capability of the composite system of this invention in the drug sensitivity detection of tumor organoids, the determination of the optimal detection time point, and the demonstration of the feasibility and advantages of 24-hour detection.

[0093] Human lung adenocarcinoma organoids were cultured using the composite system described in Example 2. After 4 days of culture, cisplatin was added at concentration gradients of 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM. An equal volume of DMSO was added to the negative control group. Each group was configured with 3 replicates.

[0094] Cellular plates were harvested at 12h, 24h, 48h, and 72h after drug administration. Intracellular ATP content was detected using ATP chemiluminescence immunoassay, and cell viability at each concentration was calculated (with the negative control group as 100%). Dose-response curves were fitted using GraphPad Prism 9 software, and IC50 values ​​at each time point were calculated. 50 value.

[0095] Each time point was independently repeated three times, and the results are expressed as mean ± SD.

[0096] IC50 of cisplatin for lung adenocarcinoma organoids at different detection time points 50 The value changes are shown in Table 4.

[0097] Table 4. IC50 of cisplatin for lung adenocarcinoma organoids at different detection time points 50 value As shown in Table 4, the 12-hour detection showed that cisplatin had a relatively short duration of action, meaning the drug had not fully penetrated into the organoids and failed to exert its cytotoxic effect. Therefore, the IC50 value was low. 50 The value was significantly high (118.6 μM), which could not accurately reflect drug sensitivity, and the data showed large variability.

[0098] 24-hour testing: IC 50 The value decreased to 63.97 μM, and the curve fit was good (R0). 2 The value >0.95 indicates a stable and reliable result. This value is close to the clinical drug concentration range (the in vitro sensitive concentration of cisplatin in lung cancer patients is usually 10-100 μM), indicating that the drug has acted sufficiently.

[0099] 48h testing: IC 50 The value was 58.2 μM, which was slightly lower than that at 24 h but there was no statistical difference (p>0.05), indicating that the drug killing effect was basically completed at 24 h, and the benefit of extending it to 48 h was limited.

[0100] 72-hour testing: IC 50 The value was 55.1 μM, slightly lower than 24 h, but the detection cycle was extended to 3 days, which could not meet the needs of rapid clinical drug sensitivity testing. In addition, prolonged culture may increase the risk of contamination and non-specific cell death due to excessive cell proliferation.

[0101] The composite system of this invention can achieve stable and accurate IC20 within 24 hours after drug addition. 50 The results showed no significant difference compared to the 48h and 72h detection results. Shorter detection times (12h) were unreliable, while longer detection times (48h, 72h) offered limited benefits and were too time-consuming. Therefore, 24h after drug administration is the optimal time for tumor organoid drug sensitivity testing using the composite system of this invention, a characteristic significantly superior to the traditional Matrigel system.

[0102] Comparative Example 1 Referring to Example 2, but without adding a microscaffold during plating, only hydrogel was mixed with cells for plating (the hydrogel and culture medium were mixed 1:1 and then directly mixed with cells). The results showed that gastric cancer organoids grew slowly; after 7 days of culture, the organoid diameter was only about 50% of that in Example 2, and the cell viability was 58.7% after 24 hours of cisplatin (50 μM) treatment (compared to 31.5% in Example 3), with the IC50 value increasing to 120.5 μM. This indicates that the microscaffold provides necessary physical support and nutrient adsorption, and is an indispensable component of the composite system.

[0103] Comparative Example 2 Referring to Example 1, but without adding AY (YGGFM-SA) to the hydrogel, AR, AQ, and AV were mixed at a volume ratio of 10:10:80 (keeping the AV ratio constant). Other steps were the same as in Example 2. Results showed that the proliferation rate of gastric cancer organoids was reduced, and cell viability was 45.2% after 24 hours of treatment with 50 μM cisplatin. 50 The value was 78.3 μM, higher than that of Example 2 (46.8 μM). This indicates that the YGGFM peptide (growth factor mimic peptide) has the effect of promoting organoid growth and improving the sensitivity of drug susceptibility testing.

[0104] Comparative Example 3 Referring to Example 1, but without adding NaHCO3 during the preparation of the microscaffold, everything else remained the same. The resulting microscaffold exhibited severe agglomeration after freeze-drying, such as... Figure 12 SEM images showed no obvious pore structure; after swelling, the particle size was uneven (50-400 μm), and the swelling rate was only 98%. When used for culture in Example 2, the organoids were unevenly distributed, and after treatment with 50 μM cisplatin for 24 h, cell viability varied greatly (RSD>25%), making it impossible to obtain reliable IC50. 50 The value indicates that pore-forming agents are crucial for the pore structure and performance of microscaffolds.

[0105] Comparative Example 4 Lung adenocarcinoma organoids were cultured in Matrigel, treated with cisplatin for 72 hours, and then ATP was measured. Results showed IC50... 50 The value was 102.3 μM, which, although lower than the 844.4 μM detected after 24 hours, was still higher than the 63.97 μM detected after 24 hours by the composite system of this invention. More importantly, the 72-hour detection cycle is much longer than the 24-hour cycle of this invention, and cannot meet the needs of rapid clinical drug sensitivity testing.

[0106] Although the present invention has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, all such modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection claimed by the present invention.

Claims

1. A sodium alginate-based hydrogel microscaffold composite system, characterized in that, It is composed of a polypeptide-modified sodium alginate hydrogel and a sodium alginate-based porous microscaffold. The polypeptide-modified sodium alginate hydrogel is prepared by mixing sodium alginate solution grafted with cell adhesion and growth factor mimicry polypeptides, wherein the polypeptides include at least RGD, QK, VN and YGGFM. The sodium alginate-based porous microscaffold is a microsphere with a porous structure prepared by spraying and freeze-drying, using sodium alginate and carboxymethyl chitosan as substrates and sodium bicarbonate as a pore-forming agent.

2. The composite system of claim 1, wherein, In the polypeptide-modified sodium alginate hydrogel, the volume ratio of the sodium alginate solution grafted with RGD, QK, VN, and YGGFM polypeptides is (5-15):(5-15):(40-60):(20-40); the molar ratio of the polypeptides to sodium alginate is 1:10-1:

30.

3. The composite system of claim 1, wherein, In the sodium alginate-based porous microscaffold, the concentration of sodium alginate solution is 1.5%-4%, the concentration of carboxymethyl chitosan solution is 1%-5%, and the volume ratio of the two is 1:0.5-1:

2.

4. The composite system of claim 1, wherein, The crosslinking agent of the microscaffold is a 30%-70% ethanol solution containing 4%-8% anhydrous calcium chloride; the particle size of the microscaffold after swelling is 100-500μm, and the swelling rate is ≥150%.

5. A process for the preparation of a sodium alginate-based hydrogel microscaffold composite system according to any one of claims 1 to 4, characterized in that, Includes the following steps: (1) RGD-sodium alginate, QK-sodium alginate, VN-sodium alginate and YGGFM-sodium alginate solutions were prepared by EDC / NHS activation method and mixed in proportion to obtain peptide-modified sodium alginate hydrogel precursor. (2) The polypeptide-modified sodium alginate hydrogel precursor solution was mixed with carboxymethyl chitosan solution, and pore-forming agent NaHCO3 was added. Calcium chloride ethanol solution was used as the crosslinking liquid. The mixture was spray-granulated, cured, washed, and freeze-dried to obtain sodium alginate-based microscaffolds. (3) The polypeptide-modified sodium alginate hydrogel precursor and sodium alginate-based microscaffold are mixed in a certain proportion to prepare the composite system.

6. The production method according to claim 5, wherein The activation and grafting conditions in step (1) are as follows: the crosslinking agent of the microscaffold is a 30%-70% ethanol solution containing 4%-8% anhydrous calcium chloride; the particle size of the microscaffold after swelling is 100-500μm, and the swelling rate is ≥150%.

7. The preparation method according to claim 5, characterized in that, The spray process parameters in step (2) are: nozzle distance from crosslinking agent liquid surface 8-20cm, pressure 0.01-0.1Pa, feed rate 5-30rpm / min; crosslinking curing time 0.5-3h, freeze drying time 2-5 days.

8. The application of the sodium alginate-based hydrogel microscaffold composite system as described in any one of claims 1-4 in the preparation of three-dimensional culture products of tumor organoids or antitumor drug sensitivity detection products.

Citation Information

Patent Citations

  • Preparation method and application of polypeptide grafted sodium alginate-chitosan gel

    CN115873266A

  • Injectable RGD-sodium alginate hydrogel as well as preparation method and application thereof

    CN118649128A

  • Sodium alginate-based hydrogel and preparation method thereof

    CN120714100A

  • Preparation process of sodium alginate-based micro-scaffold

    CN121102575A

  • Three-dimensional culture method for tumor organoids based on hydrogel and micro-scaffold

    CN121495859A